It’s been a crucial week for Glaukos Corporation (NYSE:GKOS); here’s what analysts have to say.

September 30, 2018 - By Margaret Guttierez

Glaukos Corporation (NYSE:GKOS) Logo

Glaukos Corporation (NYSE:GKOS) Ratings Coverage

Among 4 analysts covering Glaukos (NYSE:GKOS), 1 have Buy rating, 0 Sell and 3 Hold. Therefore 25% are positive. Glaukos had 9 analyst reports since April 13, 2018 according to SRatingsIntel. The firm earned “Overweight” rating on Wednesday, August 29 by JP Morgan. The firm has “Hold” rating by Stifel Nicolaus given on Friday, April 13. The rating was maintained by Stifel Nicolaus on Friday, August 3 with “Hold”. The firm has “Market Perform” rating by BMO Capital Markets given on Thursday, August 30. As per Thursday, June 21, the company rating was downgraded by J.P. Morgan. The stock of Glaukos Corporation (NYSE:GKOS) earned “Market Perform” rating by BMO Capital Markets on Wednesday, September 5. The stock has “Outperform” rating by BMO Capital Markets on Friday, June 1. The stock has “Market Perform” rating by BMO Capital Markets on Tuesday, July 10. Below is a list of Glaukos Corporation (NYSE:GKOS) latest ratings and price target changes.

05/09/2018 Broker: BMO Capital Markets Old Rating: Market Perform New Rating: Market Perform Old Target: $59 New Target: $68 Maintain
30/08/2018 Broker: BMO Capital Markets Old Rating: Market Perform New Rating: Market Perform Old Target: $44 New Target: $59 Maintain
29/08/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Overweight Old Target: $42 New Target: $75 Upgrade
03/08/2018 Broker: Stifel Nicolaus Old Rating: Hold New Rating: Hold Old Target: $32 New Target: $35 Maintain
10/07/2018 Broker: BMO Capital Markets Old Rating: Outperform New Rating: Market Perform Old Target: $42 Downgrade
21/06/2018 Broker: J.P. Morgan Rating: Hold New Target: $45.0000 Downgrade
01/06/2018 Broker: BMO Capital Markets Old Rating: Outperform New Rating: Outperform Old Target: $40 New Target: $42 Maintain
30/04/2018 Broker: J.P. Morgan Rating: Buy New Target: $49.0000
13/04/2018 Broker: Stifel Nicolaus Old Rating: Buy New Rating: Hold Old Target: $39 Downgrade

The stock decreased 0.31% or $0.2 during the last trading session, reaching $64.9. About 421,554 shares traded. Glaukos Corporation (NYSE:GKOS) has risen 54.53% since September 30, 2017 and is uptrending. It has outperformed by 38.91% the S&P500.

Glaukos Corporation, an ophthalmic medical technology company, focuses on the development and commercialization of products and procedures designed to treat glaucoma. The company has market cap of $2.29 billion. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. It currently has negative earnings. The companyÂ’s product pipeline includes iStent Inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry with the goal of achieving intraocular pressure reduction; iStent Supra suprachoroidal micro-bypass stent, which is designed to reduce intraocular pressure by accessing the suprachoroidal space in the eye; and iDose, a targeted injectable drug delivery implant that is designed to be pre-loaded into a small gauge needle and injected into the eye through a self-sealing corneal needle penetration.

Glaukos Corporation (NYSE:GKOS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: